期刊
MOLECULAR THERAPY
卷 23, 期 1, 页码 130-138出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/mt.2014.143
关键词
-
资金
- FARA/FARA Ireland (Friedreich's Ataxia Research Alliance)
- ASOGAF (Friedreich's ataxia association of Granada)
- Science and Innovation Ministry (MICINN) [BFU2010-27326]
- GVA [2009/028, 2014/014]
- Tercel [RD06/0010/0023, RD06/0010/24]
- MEC-CONSOLIDER [CSD2007-00023]
- Cinco P menos Foundation
- EUCOMM
- Fundacion Diogenes-Elche city government
- Walk on Project
- MAPFRE Foundation
The main objective of this work is to demonstrate the feasibility of using bone marrow-derived stem cells in treating a neurodegenerative disorder such as Friedreich's ataxia. In this disease, the dorsal root ganglia of the spinal cord are the first to degenerate. Two groups of mice were injected intrathecally with mesenchymal stem cells isolated from either wild-type or Fxntm1Mkn/Tg(FXN) YG8Pook (YG8) mice. As a result, both groups presented improved motor skills compared to nontreated mice. Also, frataxin expression was increased in the dorsal root ganglia of the treated groups, along with lower expression of the apoptotic markers analyzed. Furthermore, the injected stem cells expressed the trophic factors NT3, NT4, and BDNF, which bind to sensory neurons of the dorsal root ganglia and increase their survival. The expression of antioxidant enzymes indicated that the stem cell-treated mice presented higher levels of catalase and GPX-1, which are downregulated in the YG8 mice. There were no significant differences in the use of stem cells isolated from wild-type and YG8 mice. In conclusion, bone marrow mesenchymal stem cell transplantation, both autologous and allogeneic, is a feasible therapeutic option to consider in delaying the neurodegeneration observed in the dorsal root ganglia of Friedreich's ataxia patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据